← Back to Screener
Kezar Life Sciences, Inc. Common Stock (KZR)
Price$7.29
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)9.25%
Price vs S&P 500 (4W)-9.39%
VGM Score75.05
Market Capitalization$53.86M
All Metrics
Book Value / Share (Quarterly)$9.56
P/TBV (Annual)0.25x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-7.06
Price vs S&P 500 (YTD)7.73%
Net Profit Margin (TTM)-1254.16%
EPS (TTM)$-7.66
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-7.66
EPS (Annual)$-7.66
ROI (Annual)-79.96%
Cash / Share (Quarterly)$9.80
ROA (Last FY)-73.11%
EBITD / Share (TTM)$-7.96
ROE (5Y Avg)-51.78%
Operating Margin (TTM)-1383.84%
Cash Flow / Share (Annual)$-7.06
P/B Ratio0.77x
P/B Ratio (Quarterly)0.66x
Net Income / Employee (Annual)$-6,225,900
ROA (TTM)-54.83%
EPS Incl Extra (Annual)$-7.66
Current Ratio (Annual)11.52x
Quick Ratio (Quarterly)11.34x
3-Month Avg Trading Volume0.07M
52-Week Price Return76.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.97
P/S Ratio (Annual)7.69x
Asset Turnover (Annual)0.03x
52-Week High$7.55
EPS Excl Extra (Annual)$-7.66
CapEx CAGR (5Y)-46.93%
Tangible BV CAGR (5Y)38.88%
26-Week Price Return17.39%
Quick Ratio (Annual)11.34x
13-Week Price Return20.90%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.52x
Enterprise Value$-18.02M
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)25.77%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1455.29%
Cash / Share (Annual)$9.80
3-Month Return Std Dev48.11%
Net Income / Employee (TTM)$-6,225,900
ROE (Last FY)-79.96%
EPS Basic Excl Extra (Annual)$-7.66
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-7.66
ROI (TTM)-60.32%
P/S Ratio (TTM)9.50x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.94
Price vs S&P 500 (52W)46.40%
Year-to-Date Return15.90%
5-Day Price Return-1.35%
EPS Normalized (Annual)$-7.66
ROA (5Y Avg)-44.98%
Net Profit Margin (Annual)-1455.29%
Month-to-Date Return-0.27%
Cash Flow / Share (TTM)$-1.20
EBITD / Share (Annual)$-7.96
Operating Margin (Annual)-1591.77%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-49.63%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-7.66
P/TBV (Quarterly)0.31x
P/B Ratio (Annual)0.66x
Pretax Margin (TTM)-1254.16%
Book Value / Share (Annual)$9.56
Price vs S&P 500 (13W)12.04%
Beta0.43x
Revenue / Share (TTM)$0.00
ROE (TTM)-64.42%
52-Week Low$3.53
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.92est. -0.87
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.50
3.50
3.56
3.56
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KZRKezar Life Sciences, Inc. Common Stock | — | — | B | $7.29 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Kezar Life Sciences is a clinical-stage biotechnology company developing small molecule therapeutics for autoimmunity and cancer indications. The company's pipeline includes lead candidates Zetomipzomib (KZR-616) and KZR-261, designed to address significant unmet medical needs in these therapeutic areas.